AKBA vs AMCR · rev $102.7M vs P/E 18, rev $23.51B
Akebia Ther (AKBA) versus Amcor PLC (AMCR) — a side-by-side from cached financials, not a winner call.
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
Amcor PLC (AMCR) is a packaging & containers company listed on US.
Latest reported AKBA revenue for 2026-06-30 was $102.7M. Net income was -$18.0M. Revenue was up 91.8% from 2026-03-31 to 2026-06-30. AKBA currently screens at market cap $260.1M.
Latest reported AMCR revenue for 2026-06-30 was $23.51B. Net income was $1.11B. Revenue was up 362.5% from 2025-06-30 to 2026-06-30. AMCR currently screens at market cap $22.52B and trailing P/E 17.6.
AKBA currently screens at market cap $260.1M. AMCR currently screens at market cap $22.52B and trailing P/E 17.6.
Not investment advice. Open the AKBA and AMCR stock pages for the full models.
Not investment advice.